

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/002582 A3

(51) International Patent Classification⁷: **A61K 31/513**,
31/16, 31/66, 31/175, A61P 35/00, A61K 31/00, C07C
233/58, 233/59, 233/60, C07D 295/12

(21) International Application Number:
PCT/US2004/021509

(22) International Filing Date: 2 July 2004 (02.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/484,526 2 July 2003 (02.07.2003) US
60/491,616 31 July 2003 (31.07.2003) US

(71) Applicant (for all designated States except US): **GENEN-
TECH, INC.** [US/US]; 1 DNA Way, South San Francisco,
CA 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REYNOLDS, Mark**
[US/US]; 174 Linda Vista, Millbrae, CA 94030 (US). **PO-
LAKIS, Paul** [US/US]; 1449 Cortez Avenue, Burlingame,
CA 94010 (US).

(74) Agent: **BRUESS, Steven, C.**; Merchant & Gould P.C.,
P.O. Box 2903, Minneapolis, MN 55402-0903 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
26 May 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS

(57) Abstract: Compounds of the disclosure provide compositions, which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compounds, analogs, prodrugs, metabolites, and pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer, tumors, and like conditions. The disclosure also provides therapeutic methods including the administration of an effective amount of a compound of the disclosure.

WO 2005/002582 A3

INTERNATIONAL SEARCH REPORT

National Application No
PCT/US2004/021509

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/513 A61K31/16 A61K31/66 A61K31/175 A61P35/00
 A61K31/00 C07C233/58 C07C233/59 C07C233/60 C07D295/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/11699 A (UNIV BOSTON) 4 May 1995 (1995-05-04) the whole document	1, 15
X	WO 94/05291 A (SALIM AWS SHAKIR MUSTAFA) 17 March 1994 (1994-03-17) claims 1-3,7,12	1
X	WO 00/33856 A (BESSETTE STEVEN M ; ECOSMART TECHNOLOGIES INC (US); ENAN ESSAM E (US)) 15 June 2000 (2000-06-15) page 4, paragraph 9 - page 5, paragraph 2; claims 1,2,16	1
P, X	WO 2004/054497 A (KAISER SIMONE ; PLATH THOMAS (DE); REULE MATTHIAS (DE); METAGEN PHARMA) 1 July 2004 (2004-07-01) the whole document	1-15, 17, 19

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

8 December 2004

Date of mailing of the international search report

08. 04. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Greif, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/021509

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WEI E T ET AL: "AG-3-5: A CHEMICAL PRODUCING SENSATIONS OF COLD" JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, vol. 35, no. 2, 1983, pages 110-112, XP009029151 ISSN: 0022-3573 cited in the application the whole document	1-19
X	MONTELL C: "Thermosensation: Hot Findings Make TRPNs Very Cool" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 13, no. 12, 17 June 2003 (2003-06-17), pages R476-R478, XP004535113 ISSN: 0960-9822	12,13
Y	the whole document	1-11, 14-19
Y	TSAVALER LARISA ET AL: "Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 9, 1 May 2001 (2001-05-01), pages 3760-3769, XP002246273 ISSN: 0008-5472 the whole document	1-19
X	MCKEMY D D ET AL: "Identification of a cold receptor reveals a general role for TRP channels in thermosensation" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 416, 2002, pages 52-58, XP002250383 ISSN: 0028-0836	12,13
Y	page 57, left-hand column, paragraph 2 - right-hand column, paragraph 1	1-11, 14-19
P,X	WO 2004/026840 A (UNILEVER PLC ; LEVER HINDUSTAN LTD (IN); UNILEVER NV (NL)) 1 April 2004 (2004-04-01) the whole document	7,8,10
P,X	WO 03/092697 A (PAGET HUGH CHARLES EDWARD ; CRAGMONT PHARMACEUTICALS LLC (US)) 13 November 2003 (2003-11-13) the whole document	7,8,10
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/021509

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>FLEIG A ET AL: "The TRPM ion channel subfamily: molecular, biophysical and functional features" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 25, no. 12, December 2004 (2004-12), pages 633-639, XP004629294 ISSN: 0165-6147 the whole document</p> <p style="text-align: center;">-----</p>	1-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/021509

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19 (all partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula I, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula I, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula I, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula I, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula I, or a pharmaceutical composition comprising a compound of formula I, or the use of compound of formula I to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula I in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

2. claims: 1-19 (all partially), 20

A method of treating cancer comprising contacting cancerous cells with a compound of the formula II, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula II, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula II, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula II, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula II, or a pharmaceutical composition comprising a compound of formula II, or the use of compound of formula I to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula II in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition, or a compound of formula IIa.

3. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula III, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula III, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula III, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula III, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula III, or a pharmaceutical composition comprising a compound of formula III, or the use of compound of formula III to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula III in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

4. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula IV, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula IV, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula IV, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula IV, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula IV, or a pharmaceutical composition comprising a compound of formula I, or the use of compound of formula IV to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula IV in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

5. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula V, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula V, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula V, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula V, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula V, or a pharmaceutical composition comprising a compound of formula V, or the use of compound of formula V to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula V in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

6. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula VI, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula VI, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula VI, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula VI, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula VI, or a pharmaceutical composition comprising a compound of formula VI, or the use of compound of formula VI to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula VI in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

7. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula VII, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula VII, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula VII, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula VII, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula VII, or a pharmaceutical composition comprising a compound of formula VII, or the use of compound of formula I to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula VII in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

8. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula VIII, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula VIII, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula VIII, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula VIII, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula VIII, or a pharmaceutical composition comprising a compound of formula I, or the use of compound of formula VIII to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula VIII in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

9. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula IX or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula IX, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula IX, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula IX or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula IX, or a pharmaceutical composition comprising a compound of formula IX, or the use of compound of formula IX to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula IX in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

10. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula X, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula X, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula X, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula X, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula X, or a pharmaceutical composition comprising a compound of formula X, or the use of compound of formula X to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula X in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

11. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula XI, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula XI, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula XI, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula XI, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula XI, or a pharmaceutical composition comprising a compound of formula XI, or the use of compound of formula XI to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula XI in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

12. claims: 1-19 (all partially)

A method of treating cancer comprising contacting cancerous cells with a compound of the formula XII, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula XII, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula XII, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula XII, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula XII, or a pharmaceutical composition comprising a compound of formula I, or the use of compound of formula XII to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula XII in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

13. claims: 1-19 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A method of treating cancer comprising contacting cancerous cells with a compound of the formula XIII, or a method of inhibiting or killing cancerous cells comprising administering to the cells a therapeutically effective amount of compound of the formula XIII, or a method of causing apoptosis in cancerous cells comprising contacting the cells with an effective amount of a compound of formula XIII, or a method for treating a disease or condition in a mammal wherein a Trp-p-8 receptor is implicated, comprising an effective amount of compound of formula XIII, or a method for treating or preventing a Trp-p-8 receptor related condition comprising administering a compound of formula XIII, or a pharmaceutical composition comprising a compound of formula XIII, or the use of compound of formula I to prepare a medicament useful for treating or preventing a disease or Trp-p-8 related condition, or a compound of formula XIII in combination with at least one additional chemotherapeutic agent for use in treating or preventing a disease or Trp-p-8 receptor related condition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/021509

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9511699	A	04-05-1995	AU 696167 B2	03-09-1998
			AU 7976794 A	22-05-1995
			CA 2174737 A1	04-05-1995
			EP 0731712 A1	18-09-1996
			JP 9507050 T	15-07-1997
			RO 115498 B1	30-03-2000
			WO 9511699 A1	04-05-1995
			US 5858365 A	12-01-1999
WO 9405291	A	17-03-1994	AU 4973993 A	29-03-1994
			WO 9405291 A1	17-03-1994
WO 0033856	A	15-06-2000	AU 1841900 A	26-06-2000
			AU 2167000 A	26-06-2000
			AU 2167100 A	26-06-2000
			BR 9916879 A	06-11-2001
			CA 2353475 A1	15-06-2000
			CA 2353476 A1	15-06-2000
			CA 2353516 A1	15-06-2000
			CN 1329498 A	02-01-2002
			CZ 20011979 A3	17-10-2001
			EP 1137425 A1	04-10-2001
			EP 1137426 A1	04-10-2001
			EP 1137427 A1	04-10-2001
			HU 0104674 A2	29-06-2002
			ID 29393 A	30-08-2001
			JP 2002531511 T	24-09-2002
			JP 2002531512 T	24-09-2002
			JP 2002531513 T	24-09-2002
			NO 20012774 A	06-06-2001
			NZ 527850 A	30-07-2004
			PL 349028 A1	01-07-2002
			TR 200101481 T2	21-09-2001
			WO 0033856 A1	15-06-2000
			WO 0033857 A1	15-06-2000
			WO 0033858 A1	15-06-2000
			US 2003017218 A1	23-01-2003
			US 2003108622 A1	12-06-2003
			US 2003108623 A1	12-06-2003
US 2002182268 A1	05-12-2002			
US 2003017215 A1	23-01-2003			
US 2004146595 A1	29-07-2004			
US 2004156922 A1	12-08-2004			
ZA 200104611 A	13-12-2001			
WO 2004054497	A	01-07-2004	DE 10259619 A1	08-07-2004
			WO 2004054497 A2	01-07-2004
WO 2004026840	A	01-04-2004	AU 2003266321 A1	08-04-2004
			WO 2004026840 A1	01-04-2004
			US 2004067970 A1	08-04-2004
WO 03092697	A	13-11-2003	US 2003207851 A1	06-11-2003
			US 2003207903 A1	06-11-2003
			US 2003207904 A1	06-11-2003
			US 2003206873 A1	06-11-2003
			US 2003206866 A1	06-11-2003
			AU 2003222990 A1	17-11-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/021509

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03092697 A		EP 1503763 A1	09-02-2005
		WO 03092697 A1	13-11-2003
